Enhanced In Vivo tumour response from combination of carboplatin and low-dose c-myc antisense oligonucleotides

Anticancer Research

Volumn 22, Issue 4, 2002, Pages 2237-2245

  Walker, Todd L ^a   Dass, C R ^a   Burton, M A ^a  

^a CHARLES STURT UNIVERSITY   (Australia)

Author keywords

c myc oligodeoxynucleotides; Carboplatin; Osmotic pump; Phosphorothioate

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CARBOPLATIN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; OLIGOMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG MIXTURE; DRUG POTENTIATION; FEMALE; GENE EXPRESSION; MALE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; RAT; RODENT; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; CARBOPLATIN; CELL DIVISION; DISEASE MODELS, ANIMAL; GENES, MYC; KINETICS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RATS; THIONUCLEOTIDES;

EID: 0036332138     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Antisense oligonucleotides as therapeutic agents
2. Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells - A novel therapy in prostate cancer
3. Efficacy of ion-exchange resins for anti-tumour drug delivery
4. Synthetic oligonucleotides-useful molecules - A review
5. Block of c-myc expression by antisense oligonucleotides inhibits proliferation of human thyroid carcinoma cell lines
6. C-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice
7. Progress in antisense oligonucleotide therapeutic
8. Oligonucleotides as modulators of cancer gene expression
9. Targeting gene therapy to cancer - A review
10. The effect of cisplatin and carboplatin on c-myc promoter in erythroleukemic cells
11. Modification of the sensitivity to cisplatin with c-myc over-expression or down-regulation in colon cancer cells
12. Regulatory elements that modulate expression of human c-myc
13. A FOS protein is present in a complex that binds a negative regulator of MYC
14. 1
15. Modulation of cellular functions in retro-orbital fibroblasts using antisense oligonucleotides targeting the c-myc protooncogene
16. Differential oncogene amplification in tumour cells from a patient treated with cisplation and 5-FU
17. Antitumour effect of c-myc antisense phosphorothioate oligonucleotides on human melanoma cells in vitro and in mice
18. Absence of functional lymphatics within a murine sarcoma: A molecular and functional evaluation
19. Differential regulation of the c-MYC P1 and P2 promoters in the absence of functional tumor suppressors: Implications for mechanisms of deregulated MYC transcription
20. Enhancement of sensitivity of urinary bladder tumour cells to cisplatin by c-myc antisense oligonucleotide
21. Antitumour activity of antisense oligonucleotide inhibitors targeted to ras and raf kinase isoforms
22. Role of extracellular matrix assembly in interstitial transport in solid tumours
23. The c-myc story: Where we've been, where we seem to be going
24. Enhanced anti-tumor effects with microencapsulated c-myc antisense oligonucleotide
25. Antisense oligonucleotides - A new class of potential anti-aids and anticancer drugs
26. Myc oncogenes: The enigmatic family
27. Abnormal c-myc oncogene DNA methylation in human bladder cancer possible role in tumor progression
28. Relationship between proto-oncogene expression and apoptosis induced by anticancer drugs in human prostate tumour cells
29. Antileukemia effect of c-myc 3′-5′ phosphoramidate antisense oligonucleotides in vivo
30. Cisplatin responsive sequences in the human c-myc promoter
31. Antisense c-myc retroviral vector suppresses established human prostate cancer
32. Oncotic pressure in solid tumours is elevated
33. Effects of c-myc oncogene modulation on differentiation of human small cell lung carcinoma cell lines
34. High-dose chemotherapy regimens for solid tumors
35. Cisplatin chemotherapy results in selection of tumour cells with elevated c-myc expression
36. Status of antisense oligodeoxynucleotides as therapeutic agents
37. A method for intratumoural continuous infusion of antisense oligodeoxynucleotides
38. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer
39. Anti-c-myc DNA increases differentiation and decreases colony formation by HL-60 cells
40. Antisense oligodeoxynucleotide methylphosphonate inhibition of mouse c-myc p65 protein expression in E mu-c-myc transgenic mice
41. Antisense c-myc inhibition of lymphoma growth
42. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitts lymphoma cell growth
43. Antisense c-myc oligonucleotide uptake and activity
44. Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells
45. Carboplatin as opposed to cisplatin does not stimulate the expression of the human immunodeficiency virus long terminal repeat sequences